Related Experiment Video
Updated: Mar 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals' views
Yishen Wang1, Beata Bajorek2,3
1Graduate School of Health-Pharmacy, The University of Technology Sydney, Sydney, NSW, 2007, Australia. Yishen.Wang@student.uts.edu.au.
Insights
Health professionals
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Stroke prevention in atrial fibrillation (AF) is complex due to patient factors and antithrombotic properties.
- Decision-making challenges can lead to underutilization of antithrombotic therapy and poor outcomes.
- Exploring health professionals' current views on antithrombotic therapy decision-making is crucial for improving stroke prevention.
Purpose of the Study:
- To identify emerging themes in health professionals' perspectives on antithrombotic therapy decision-making for AF stroke prevention.
- To understand the factors influencing treatment choices between warfarin and non-vitamin K antagonist oral anticoagulants (NOACs).
Main Methods:
- Qualitative study using face-to-face interviews with pharmacists, specialists, general practitioners, and nurses.
- Interviews conducted in Sydney, Australia (August-October 2014) until theme saturation.
- Manual inductive coding of interview transcripts to identify key themes.
Main Results:
- Comprehensive assessment is needed but often omits bleeding risk and medication safety.
- Disciplinary differences exist: warfarin is often first-line, but NOACs are preferred by neurologists/hematologists.
- GPs/specialists focus on prescription, while pharmacists/nurses emphasize patient medication management.
Conclusions:
- Antithrombotic therapy decision-making is often preference-based rather than systematic.
- Varied disciplinary focus can fragment the decision-making process.
- Improving stroke prevention requires addressing these varied perspectives and ensuring comprehensive patient assessment.
Abstract:
Background For stroke prevention in patients with atrial fibrillation (AF), the decision-making around antithrombotic therapy has been complicated by older age, multiple comorbidities, polypharmacy and the different pharmacological properties of warfarin and the nonvitamin K antagonist oral anticoagulants (NOACs). The complexity of decision-making has been associated with a reluctance by health professionals to use antithrombotic therapy, leading to poor clinical outcomes. In order to improve stroke prevention in patients with AF, the contemporary perspectives of health professionals on the decision-making around antithrombotic therapy needs exploration. Objective To elicit emerging themes describing health professionals' perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Setting Sydney metropolitan area of New South Wales, Australia. Method A qualitative study based on face-to-face interviews was conducted from August to October 2014. Seven pharmacists, seven specialists, six general practitioners and six nurses practising in the Sydney metropolitan area and managing antithrombotic therapy for AF were interviewed until theme saturation was achieved in each subgroup. Interview transcripts were analysed using manual inductive coding. Main outcome measure Emerging themes describing health professionals' perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Results Three overarching themes emerged. (1) Comprehensive assessment is necessary for decision-making but is not always implemented. Health professionals mostly focused on stroke risk assessment, not on the bleeding risk and medication safety issues. (2) Health professionals from different disciplines have different preferences for antithrombotic therapies. Although the majority of health professionals considered warfarin as the first-line therapy, NOACs were preferred by neurologists and haematologists. (3) Health professionals focused on different aspects of the decision making process: GPs and specialists were concerned about the appropriate prescription of antithrombotics, while pharmacists and nurses focused on daily medication management by patients. Conclusion The decision-making process appears to be partially preference based rather than systematic, and health professionals from various disciplines focus on different parts of the decision-making process.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care

